6 Things to Know About Infliximab as Ulcerative Colitis Treatment

Share on Facebook
A recent study examined the efficacy of infliximab as a treatment for moderate to severe ulcerative colitis, according to a Medscape report.

The study included 134 ulcerative colitis patients. Of the subjects studied, 28 percent had acute severe ulcerative colitis, 38 percent had steroid-dependency and 33 percent had steroid-refractoriness.

●    Rate of clinical response at week eight: 87 percent
●    Rate of clinical remission at week eight: 45 percent
●    Long-term clinical response: 71 percent
●    Long-term clinical remission: 52 percent
●    Adverse events affected 15 percent of patients
●    Mucosal healing was the sole factor influencing long-term response.

More Articles on Gastroenterology:
9 Things Gastroenterologists Need to Know About the Gut Microbiome
5 Recent GI-Driven Center Openings & Plans
Does Patient Satisfaction Affect Colorectal Caner Treatment Outcomes?

© Copyright ASC COMMUNICATIONS 2012. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

New from Becker's ASC Review

Dr. Brennan Spiegel to lead new Cedars-Sinai research, education center

Read Now